The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,956.00
Bid: 1,964.00
Ask: 1,966.00
Change: -4.00 (-0.20%)
Spread: 2.00 (0.102%)
Open: 1,994.00
High: 2,000.00
Low: 1,956.00
Prev. Close: 1,960.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: BoE Stimuli Push Up Stocks But Depress Sterling

Thu, 04th Aug 2016 16:04

LONDON (Alliance News) - Stocks in London ended firmly in the green Thursday, while the pound took a big hit, after the Bank of England announced a substantial package of stimuli including an interest rate cut to a new record low and an expansion in asset purchases, after recent macroeconomic data had pointed to a slowdown in the UK economy following the Brexit referendum.

The BoE also drastically downgraded its growth projections as the Leave vote heightened uncertainty and the sharp depreciation in sterling triggered an upward revision to the inflation forecast.

The Monetary Policy Committee voted unanimously to cut UK interest rates by 25 basis points to 0.25%, the first rate cut since 2009. Governor Mark Carney said in a press conference following the decision that there is room for further cuts to rates, but made it clear that they will not go as low as to become negative.

"I'm not a fan of negative rate interest rates," Carney said, speaking to journalists. The governor signalled that the lower bound of rates will be close to zero, but always "a positive number".

Alongside the cut to rates, the central bank expanded the size of its Asset Purchase Facility programme, with the increase totalling GBP170 billion as a whole. Purchases of UK government bonds will increase by GBP60 billion to GBP435 billion. This measure was passed after the MPC voted 6-3, with policymakers Kristin Forbes, Ian McCafferty, and Martin Weale against the proposition, preferring no change.

The MPC also decided on the purchase of up to GBP10 billion of UK corporate bonds, with the decision approved with 8-1 majority.

In addition, the MPC voted unanimously to introduce a Term Funding Scheme that will be financed by the issuance of central bank reserves, aimed to help reinforce the transmission of the interest rate cut to the real economy. The BoE said this will operate as part of the asset purchasing programme.

The value of the lending in the TFS will be determined by usage of the scheme, the bank said, and could reach "around GBP100 billion". Carney added that UK banks have "no excuse" not to pass on the rate cut.

The governor said that, at this meeting, "everyone in the MPC though this economy needed stimulus". Carney noted that the Leave vote in the referendum represents a "regime change", but said the UK is "one of the most flexible economies in the world".

Oanda senior market analyst Craig Erlam said that, with this decision, "the BoE became one of the only central banks to announce a stimulus package that appears to have, at least for now, exceeded market expectations and satisfy investors in a way that other central banks have failed this year."

According to the Inflation Report released alongside the monetary policy decision, the economy is likely to see little growth in the second half of 2016. Business investment is set to continue to fall in the near term on slower demand growth. Gross domestic product growth is forecast to ease to 0.1% in the third quarter of 2016. The bank slashed its GDP growth outlook for 2017 to 0.8% from 2.3%. Similarly, the projection for 2018 was trimmed to 1.8% from 2.3%.

The fall in sterling is set to push up inflation in the near-term. Inflation is forecast to return to the 2% target in late 2017 and overshoot this target throughout 2018.

Sterling dropped immediately after the BoE's decision, having being quoted at USD1.3316 just prior. At the London equities close, the pound stood at 1.3138, compared to USD1.3327 at the same time Wednesday. The currency, however, remained way above the 31-year low of USD1.2797 reached in early July, with the results of the EU referendum still fresh.

Contrary to the pound, London stocks shot higher after the BoE decision, with the FTSE 100 index ending up 1.6%, or 105.76 points, at 6,740.16. The FTSE 250 of mid-caps rose 1.5%, or 247.19 points, to 17,244.32, and the AIM All-Share added 0.6%, or 4.33 points, to end at 761.66.

Aviva ended as the biggest blue-chip gainer, up 6.7%. The insurer's chief executive told journalists he is unsure about what an interest rate cut in the UK will achieve, after the blue-chip insurer had posted higher operating profit and hiked its dividend on a strong first half for its life and fund management businesses.

Aviva CEO Mark Wilson, speaking before the BoE's decision, said there is not currently a large amount of household debt in the UK and borrowing rates are already "incredibly cheap". Wilson was sanguine when questioned about any impact Aviva could face from interest rates remaining low or, indeed, falling further.

He said Aviva has been structured to ensure liabilities and assets move together, adding the group has "deliberately positioned" itself as a "blue-chip haven" against low interest rates.

Aviva declared an interim dividend of 7.42p, up from 6.75p a year prior, driven by strong performances in its life insurance and fund management operations. It said it remains on track to deliver on its plan to increase its dividend payout ratio to 50% of operating earnings per share by the end of 2017 from 42% in 2015.

RSA Insurance also reported first-half results, delivering a big rise in underwriting profit and declaring an increase in dividend. Underwriting profit for the first half increased 63% to GBP119.0 million from GBP73.0 million. This was driven by a 3.1 percentage point improvement in RSA's attritional loss ratio to 54.8% from 57.9%. The group declared an interim dividend of 5.0 pence per share, up 43% from 3.5p a year prior. RSA shares rose 1.4%.

Shares in Standard Chartered added 4.3% after Standard & Poor's Global upgraded the lender to Hold from Sell, while HSBC Holdings rose 2.5% after Merrill Lynch lifted its recommendation on the bank to Buy from Underperform, according to traders.

Hikma Pharmaceuticals missed the gains, ending as by far the worst blue-chip performer, down 17%. The drug company late Wednesday said it expects full-year operating profit within its Generics division to be hit by changes in revenue mix, but maintained its guidance on its other two divisions.

The company noted that it had experienced some delays in certain product approvals, but said the impact to revenue should be offset by higher contract manufacturing revenue. However, Hikma said the change in revenue mix is expected to hit profitability in 2016, along with higher than expected costs resulting from the acceleration in timing of certain pipeline-related litigation.

Hikma said it now expects core operating profit within its Generics division to come in within the range of USD30.0 million and USD40.0 million for 2016, below the USD46.0 million reported for 2015. Hikma was downgraded to Neutral from Buy by Citigroup and to Hold from Add by Numis.

In mainland Europe, the CAC 40 index in Paris the DAX 30 in Frankfurt both added 0.6%. At the equities close, the euro was quoted at USD1.1134, compared to USD1.1175 at the same time Wednesday.

In New York, stocks were higher at the European equities close, with the Dow 30 flat, and the S&P and the Nasdaq Composite both up 0.1%.

Gold was quoted at USD1.363.19 an ounce at the equities close, against USD1,357.14 on Wednesday, while Brent oil stood at USD43.30 a barrel, compared to USD42.47 on Wednesday.

Highlights in the economic calendar Friday are UK Halifax house prices at 0830 BST, and US nonfarm payrolls at 1330 BST. The US Baker Hughes US oil rig count is at 1800 BST.

In the UK corporate calendar, Royal Bank of Scotland Group, Ibstock, William Hill, Esure Group, and Kennedy Wilson Europe Real Estate all report half-year results. Bellway and S&U issue trading statements.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
6 Mar 2023 09:48

LONDON BROKER RATINGS: DB cuts Reckitt; Jefferies likes Tesco

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
1 Mar 2023 09:52

LONDON BROKER RATINGS: Canaccord says sell Future; Investec likes RWS

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
27 Feb 2023 09:38

Berenberg raises target price on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Read more
27 Feb 2023 09:26

LONDON BROKER RATINGS: Citi cuts Quilter to 'sell'; Goldman likes GSK

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
24 Feb 2023 09:37

LONDON BROKER RATINGS: SocGen cuts Burberry; BofA cuts WH Smith

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
23 Feb 2023 09:54

Hikma Pharmaceuticals profit halves in 2022 on Generics impairment

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported a dip in annual revenue for 2022, as profit tumbled due to high inflation and adjustments regarding expectations for its Generics business.

Read more
23 Feb 2023 09:02

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.

Read more
23 Feb 2023 07:59

Competition in generics sees Hikma Pharmaceuticals's profits decline by a tenth

(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
22 Feb 2023 21:50

Hikma accuses Amarin of suppressing generic versions of heart pill

Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals

*

Read more
16 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Friday 17 February 
Allianz Technology Trust PLCFull Year Results
Kingspan Group PLCFull Year Results
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
Monday 20 February 
Bank of Cyprus Holdings PLCFull Year Results
Georgia Capital PLCFull Year Results
Goldplat PLCFull Year Results (TBC)
LungLife AI IncFull Year Results
Tristel PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 21 February 
Antofagasta PLCFull Year Results
BHP Group LtdHalf Year Results
Blancco Technology Group PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
HSBC Holdings PLCFull Year Results
InterContinental Hotels Group PLCFull Year Results
Safestore Holdings PLCTrading Statement
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Trifast PLCTrading Statement
Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
25 Jan 2023 09:33

LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
18 Jan 2023 15:07

Director dealings: Hikma Pharmaceuticals director snaps up shares

(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.

Read more
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.